期刊文献+

磺达肝癸钠治疗合并肾功能不全的急性冠状动脉综合征的安全性研究 被引量:2

下载PDF
导出
摘要 目的观察对比磺达肝癸钠和依诺肝素钠对合并肾功能不全的急性冠状动脉综合征患者的安全性。方法将合并肾功能不全的急性冠状动脉综合征患者136例分为对照组(67例)治疗组(69例),两组基础治疗相同,对照组给予依诺肝素钠0.1ml/10kg,皮下注射,每12小时1次,连用7 d。治疗组给予磺达肝癸钠2.5 mg/d,皮下注射,1次/d,连用7d。观察治疗7 d及30 d后出血事件发生情况,比较两组的安全性。结果 7 d后,治疗组与对照组严重出血(颅内出血、腹膜后出血、消化道出血)的发生例数比较,差异无统计学意义(P>0.05)。轻度出血(注射部位皮下瘀斑、牙龈出血、鼻出血、血尿、便潜血)并发症例数均较对照组明显减少,差异有统计学意义(P<0.05)。30 d后,严重出血及轻度出血并发症例数均较对照组明显减少(P<0.05)。结论磺达肝癸钠治疗合并肾功能不全的急性冠状动脉综合征安全性良好。
作者 陈红光
出处 《中国实用医药》 2014年第3期136-137,共2页 China Practical Medicine
  • 相关文献

参考文献3

  • 1Pham PA, Pham PT, Pham PC, et al.Implications of bleeding in acuteeoronary syndrome and pereutaneous coronary intervention. VascularHealth and Risk Management, 2011,7(5):551-567.
  • 2Yusuf S, Mehta SR, Chrolavicius S, et al.Comparison of fondapari- nuxand enoxaparin in acute coronary syndromes. N Engl J Med, 2006, 354(14) : 1464-1476.
  • 3Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondapafinux onmortality and reinfarction in patients with acute ST-segment elevationmyocardial infarction: the OASIS-6 randomized trial. JAMA, 2006,295(13) :1519-1530.

同被引文献30

  • 1宋莉,颜红兵.磺达肝癸钠在急性冠脉综合征治疗中的应用[J].中国心血管病杂志,2010,38(5):471.
  • 2杨超,李彦,杨永忠.磺达肝癸钠对非ST段抬高急性冠脉综合征的疗效与安全性的研究[J].药物与临床,2013,10(3):91-95.
  • 3PHAM P A,PHAM P T,PHAM P C,et al. Implica- tions of bleeding in acute coronary syndrome and per- cutaneous coronary intervention[J]. Vasc Health Risk Manag,2011,7:551- 567.
  • 4DAVIDSON S J,WADHAM P,ROGERS L,et al. En- dothelial cell damage in heparin-induced thrombocyto- penia[J]. Blood Coagul Fibrinolysis, 2007,18 ( 4 ) : 317 -320.
  • 5WARKENTIN T E. HIT paradigms and paradoxes [J]. J Thromb Haemost,2011,9:105-117.
  • 6WARKENTIN T E, DAVIDSON B L, BULLER H R,et al. Prevalence and risk of preexisting heparin-in-duced thrombocytopenia antibodies in patients with a- cute VTE[J]. Chest, 2011,140 : 366 - 373.
  • 7LEVINE R L, HERGENROEDER G W, FRANCIS J L,et al. Heparin-platelet factor 4 antibodies in inten- sive care patients: an observational seroprevalenee study[J]. J Thromb Thrombolysis, 2010, 30:142 - 148.
  • 8HANNA E B,GLANCY D L,SAUCEDO J F. Anti- platelet and anticoagulant therapies in acute coronary syndromes[J]. Cardiovase Drugs Ther, 2010,24 : 61 - 70.
  • 9SALEM M,ELREFAI S,SHRIT M A,et al. Fondapa- rinux thromboprophylaxis-associated heparin-induced thrombocyto-penia syndrome complicated by arterial thrombotic stroke [J]. Thromb Haemost, 2010, 104 : 1071-1072.
  • 10VAN REES VELL1NGA T E,PETERS R J ,YUSUF S, et al. Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organiza- tion for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial[J]. Am Heart J,2010, 160:1049-1055.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部